IV LBH589

Phase 2Small molecule

Novartis

IV LBH589 is one of 84 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Falciparum MalariaActive, not recruiting

MalariaActive, not recruiting

Breast CancerActive, not recruiting

Plasmodium Falciparum MalariaPhase 2

Active, not recruiting

MalariaPreclinical

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Adenocard

Astellas

Preclinical

1 3

IV LBH589

Novartis

Phase 2

1 4

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 5

Spravato

WWim Janssens

Preclinical

2 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Avastin

Roche

Preclinical

4 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Plasmodium falciparum malaria1 trial

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

Completed· Novartis logo

Novartis·Phase 2·NCT04675931·254 enrolled

Malaria1 trial

Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study

Completed·RRESnTEC, Institute of Research·N/A·NCT06472258·104 enrolled

Breast Cancer1 trial

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT00788931·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IV LBH589. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV LBH589 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV LBH589. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

IV LBH589

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Plasmodium falciparum malaria1 trial

Malaria1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News